Marie Kim Wium-Andersen1, David Dynnes Orsted1, Børge Grønne Nordestgaard2. 1. Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Denmark; The Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. 2. Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Denmark; The Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Denmark; The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen University Hospital, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.. Electronic address: Boerge.Nordestgaard@regionh.dk.
Abstract
BACKGROUND: Elevated levels of plasma C-reactive protein (CRP) have been associated with many diseases including depression, but it remains unclear whether this association is causal. We tested the hypothesis that CRP is causally associated with depression, and compared these results to those for cancer, ischemic heart disease, chronic obstructive pulmonary disease, and all-cause mortality. METHODS: We performed prospective and instrumental variable analyses using plasma CRP levels and four CRP genotypes on 78,809 randomly selected 20- to 100-year-old men and women from the Danish general population. End points included hospitalization or death with depression and somatic diseases, prescription antidepressant medication use, and all-cause mortality. RESULTS: A doubling in plasma CRP yielded an observed odds ratio (OR) of 1.28 (95% confidence interval [CI]: 1.23-1.33) for hospitalization or death with depression, whereas for genetically elevated CRP, the causal OR was .79 (95% CI: .51-1.22; observed vs. causal estimate, p = .03). For prescription antidepressant medication use, corresponding ORs were 1.12 (1.11-1.15) and .98 (.83-1.15; p = .08). These results were similar to those for risk of cancer (p = .002), ischemic heart disease (p = 4 × 10(-99)), chronic obstructive pulmonary disease (p = 6 × 10(-86)), and all-cause mortality (p = .001) examined in the same individuals. CONCLUSIONS: Elevated CRP was associated with increased risk of depression in individuals in the general population, but genetically elevated CRP was not. This indicates that CRP per se is not a causal risk factor for depression.
BACKGROUND: Elevated levels of plasma C-reactive protein (CRP) have been associated with many diseases including depression, but it remains unclear whether this association is causal. We tested the hypothesis that CRP is causally associated with depression, and compared these results to those for cancer, ischemic heart disease, chronic obstructive pulmonary disease, and all-cause mortality. METHODS: We performed prospective and instrumental variable analyses using plasma CRP levels and four CRP genotypes on 78,809 randomly selected 20- to 100-year-old men and women from the Danish general population. End points included hospitalization or death with depression and somatic diseases, prescription antidepressant medication use, and all-cause mortality. RESULTS: A doubling in plasma CRP yielded an observed odds ratio (OR) of 1.28 (95% confidence interval [CI]: 1.23-1.33) for hospitalization or death with depression, whereas for genetically elevated CRP, the causal OR was .79 (95% CI: .51-1.22; observed vs. causal estimate, p = .03). For prescription antidepressant medication use, corresponding ORs were 1.12 (1.11-1.15) and .98 (.83-1.15; p = .08). These results were similar to those for risk of cancer (p = .002), ischemic heart disease (p = 4 × 10(-99)), chronic obstructive pulmonary disease (p = 6 × 10(-86)), and all-cause mortality (p = .001) examined in the same individuals. CONCLUSIONS: Elevated CRP was associated with increased risk of depression in individuals in the general population, but genetically elevated CRP was not. This indicates that CRP per se is not a causal risk factor for depression.
Authors: Manish K Jha; Abu Minhajuddin; Cherise Chin-Fatt; Tracy L Greer; Thomas J Carmody; Madhukar H Trivedi Journal: J Psychiatr Res Date: 2019-03-20 Impact factor: 4.791
Authors: Y Milaneschi; F Lamers; W J Peyrot; A Abdellaoui; G Willemsen; J-J Hottenga; R Jansen; H Mbarek; A Dehghan; C Lu; D I Boomsma; B W J H Penninx Journal: Mol Psychiatry Date: 2015-06-30 Impact factor: 15.992
Authors: D Galan; B I Perry; V Warrier; C C Davidson; O Stupart; D Easton; G M Khandaker; G K Murray Journal: Sci Rep Date: 2022-09-03 Impact factor: 4.996
Authors: Bram P Prins; Ali Abbasi; Anson Wong; Ahmad Vaez; Ilja Nolte; Nora Franceschini; Philip E Stuart; Javier Guterriez Achury; Vanisha Mistry; Jonathan P Bradfield; Ana M Valdes; Jose Bras; Aleksey Shatunov; Chen Lu; Buhm Han; Soumya Raychaudhuri; Steve Bevan; Maureen D Mayes; Lam C Tsoi; Evangelos Evangelou; Rajan P Nair; Struan F A Grant; Constantin Polychronakos; Timothy R D Radstake; David A van Heel; Melanie L Dunstan; Nicholas W Wood; Ammar Al-Chalabi; Abbas Dehghan; Hakon Hakonarson; Hugh S Markus; James T Elder; Jo Knight; Dan E Arking; Timothy D Spector; Bobby P C Koeleman; Cornelia M van Duijn; Javier Martin; Andrew P Morris; Rinse K Weersma; Cisca Wijmenga; Patricia B Munroe; John R B Perry; Jennie G Pouget; Yalda Jamshidi; Harold Snieder; Behrooz Z Alizadeh Journal: PLoS Med Date: 2016-06-21 Impact factor: 11.069